AOD-9604 vs Compounded Tirzepatide
A side-by-side research comparison of AOD-9604 and Compounded Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AOD-9604 | Compounded Tirzepatide |
|---|---|---|
| Full name | Advanced Obesity Drug Fragment 176-191 (Modified) | Compounded Tirzepatide (503B Pharmacy) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Compounded medication |
| Mechanism | Mimics the lipolytic domain of growth hormone (hGH 176-191), stimulating fat oxidation and inhibiting de novo lipogenesis through pathways independent of IGF-1 and growth signaling. | Dual agonist of both GLP-1 and GIP receptors. GLP-1 activation suppresses appetite and slows gastric emptying. GIP activation enhances fat metabolism, improves insulin sensitivity, and may protect against muscle loss. |
| Molecular weight | 1815.08 Da | 4813.45 Da |
| Half-life | ~2-3 hours | ~5 days |
| Bioavailability | ~90% subcutaneous | ~80% subcutaneous |
| Typical dose | 300 mcg | 2.5-15 mg |
| Frequency | Daily (morning, fasted) | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
AOD-9604 reported benefits
- Fat loss without muscle wasting
- No effect on blood sugar
- Cartilage repair properties
- No HGH-related side effects
Compounded Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Dual incretin pathway activation
- Better muscle preservation
- Improved A1c
- Cardiovascular protection
- Reduced insulin resistance
Related comparisons
Research and educational reference only. Not medical advice.